We use cookies to understand how you use our site and to improve the overall user experience. This includes personalizing content and advertising. Read our
Privacy Policy
At Profacgen, our custom PEGylation services deliver comprehensive bioconjugation solutions for therapeutic proteins, peptides, oligonucleotides, and small molecules. Conjugation with polyethylene glycol has proven to be one of the most successful and broadly applicable approaches for improving the solubility, stability, and pharmacokinetic profile of biopharmaceuticals, as well as reducing the immunogenicity of therapeutic proteins, antibody-drug conjugates, and other biological modalities.
Figure 1. PEGylation of therapeutic proteins and peptides for enhanced pharmacological properties. (Adapted from Li et al., 2024)
Our specialized chemistry team brings deep expertise in protein bioconjugation and PEGylation strategy development. We recognize that every molecular target presents unique challenges arising from its specific amino acid composition, three-dimensional structure, post-translational modifications, and intended therapeutic application. Successful PEGylation requires case-by-case optimization of reagent selection (reactive chemistry, PEG size, architecture), reaction conditions (pH, temperature, stoichiometry, time), and purification strategy. We work closely with you to design and execute the optimal PEGylation approach that achieves your specific development objectives while preserving the biological activity essential for therapeutic efficacy.
Background: PEGylation Chemistry
PEGylation chemistry exploits the nucleophilic reactivity of specific amino acid side chains and functional groups to form stable covalent linkages with electrophilically activated PEG reagents. The rational design of a PEGylation strategy requires a thorough understanding of both the target molecule's reactive surface landscape and the reaction mechanisms of available PEGylation chemistries.
Lysine-targeted PEGylation uses NHS ester or carbonate-activated PEGs to react with the ε-amino group of lysine residues and the α-amino group at the N-terminus. This approach is broadly applicable because most proteins contain multiple surface-exposed lysines. However, the abundance of reactive sites typically generates a heterogeneous mixture of positional isomers with varying degrees of PEG substitution, necessitating extensive chromatographic separation to obtain homogeneous products. Modern strategies to achieve site-selective lysine PEGylation include exploiting pH differences between the more basic N-terminal α-amine (pKa ~7.6–8.0) and lysine ε-amines (pKa ~10.0–10.5) for selective N-terminal modification at mildly acidic pH, and using sterically demanding branched PEG reagents that preferentially react at the most accessible lysine sites.
Cysteine-targeted PEGylation offers superior site specificity because the free thiol group of cysteine is uniquely reactive among naturally occurring amino acid side chains under near-neutral pH conditions. Maleimide-activated PEGs react selectively with thiols at pH 6.5–7.5 to form stable, non-reversible thioether bonds. For proteins that lack accessible surface cysteines, genetic engineering can introduce a unique cysteine residue at a carefully chosen location distal from binding interfaces and active sites. This approach enables truly site-specific, stoichiometric PEGylation that yields a homogeneous product with simplified analytical characterization and regulatory documentation.
Other chemistries expand the PEGylation toolkit for specialized applications. Carboxyl-targeted PEGylation uses amine-activated PEGs conjugated to aspartate, glutamate, or C-terminal carboxyl groups via carbodiimide-mediated coupling. Glycan-targeted PEGylation employs hydrazide-activated PEGs that react with aldehyde groups generated by mild sodium periodate oxidation of carbohydrate cis-diols, enabling conjugation at glycosylation sites. Click chemistry PEGylation uses strain-promoted azide-alkyne cycloaddition (SPAAC) between an azide-functionalized PEG and a strained alkyne (DBCO) installed on the protein, offering bioorthogonal reactivity that proceeds efficiently in complex biological environments without side reactions.
Figure 1. Schematic diagram of site-specific PEGylation strategies. (Ma et al., 2025)
Both stable (permanent) and releasable (cleavable) linker options are available. Stable linkages create new pharmaceutical entities with permanently altered pharmacokinetics. Releasable linkages, including ester, hydrazone, and enzyme-cleavable peptide linkers, enable triggered PEG detachment under specific physiological conditions, which can be advantageous when the PEG shield needs to be removed at the target site to expose the therapeutic activity.
Our PEGylation Services
Profacgen provides specialized PEGylation services across two major molecular categories:
Protein and Peptide PEG Conjugation
PEGylation of proteins and peptides provides multiple advantages including reduced or eliminated immunogenicity, decreased aggregation propensity, enhanced proteolytic stability, improved thermal stability, and extended circulating half-life.
Lysine-directed PEGylation with NHS ester and carbonate PEGs
Cysteine-directed site-specific PEGylation with maleimide, iodoacetyl, and vinyl sulfone PEGs
N-terminal selective PEGylation using reductive amination or transamination chemistries
Glycan-targeted PEGylation via periodate oxidation and hydrazide chemistry
Click chemistry (SPAAC) PEGylation for bioorthogonal conjugation
Process optimization for PEG molecular weight, degree of substitution, and positional selectivity
Attachment of PEG to small-molecule drugs alters pharmacokinetic properties by modulating solubility, plasma protein binding, tissue distribution, metabolic stability, and renal clearance.
Stable linker PEGylation for sustained half-life extension
Releasable linker PEGylation with ester, hydrazone, or enzyme-cleavable bonds for triggered drug release
Linear, branched (Y-shaped), and forked PEG architectures
One-stop service: reagent supply or custom synthesis, PEGylation, purification, and characterization
Support for exploratory research through preclinical process development
Documentation suitable for regulatory submission packages (IND, NDA)
PEGylation Workflow
Our standard PEGylation service workflow encompasses the following stages:
Project consultation and strategy design: Comprehensive evaluation of target molecule properties (sequence, structure, glycosylation, aggregation propensity); selection of optimal PEGylation chemistry, site, and PEG architecture; definition of analytical methods and acceptance criteria; preparation of a detailed project proposal with timeline and milestones
Reagent procurement or synthesis: Selection from catalog PEG reagents or custom synthesis of novel PEG derivatives with defined molecular weight, functionality, and purity grade
Conjugation development and optimization: Systematic screening and optimization of reaction conditions (pH, buffer composition, temperature, PEG-to-protein stoichiometry, reaction time) to maximize conjugation yield, mono-PEGylation selectivity, and activity retention
Purification and isolation: Chromatographic separation (size-exclusion, ion-exchange, reversed-phase, hydrophobic interaction) to isolate mono-PEGylated product from multi-PEGylated species, unreacted protein, and free PEG; process development for reproducible purification at target scale
Analytical characterization: Comprehensive analytical package including molecular weight confirmation by MALDI-MS or ESI-MS; purity assessment by SEC-HPLC and SDS-PAGE; PEGylation site determination by peptide mapping with LC-MS/MS; bioactivity evaluation by relevant functional assays; stability assessment under accelerated and real-time storage conditions
Scale-up and technology transfer: Process scale-up from milligram to gram quantities; batch consistency evaluation; technology transfer documentation for manufacturing partners; regulatory support and CMC documentation
Why Choose Our PEGylation Services?
Specialized expertise: Dedicated team of protein bioconjugation chemists with extensive experience in PEGylation method development across diverse protein classes including enzymes, antibodies, cytokines, growth factors, and coagulation factors.
Customized strategies: Every project receives individualized evaluation, strategic design, and protocol optimization rather than one-size-fits-all approaches. We select the optimal chemistry, site, and PEG architecture for your specific molecule and therapeutic goals.
High-quality standards: Rigorous analytical characterization at every stage ensures product quality, batch-to-batch consistency, and comprehensive documentation. All processes are conducted under controlled conditions with detailed batch records.
Full-service integration: Seamless capabilities spanning reagent supply, custom synthesis, conjugation, purification, analytics, stability testing, and regulatory documentation within a single organization.
Flexible scale and engagement: Services available from milligram research scale to gram-scale process development, with technology transfer to GMP manufacturing partners and support for programs from discovery through commercialization.
Representative Case Studies
Case Study 1: Rescue of an Aggregation-Prone Cytokine Through Site-Specific PEGylation
Background:
A therapeutic cytokine program was stalled because the lead candidate aggregated irreversibly at concentrations above 0.5 mg/mL, preventing formulation at therapeutic doses and causing immunogenicity concerns due to particle formation.
Approach:
Profacgen performed computational analysis (PyMOL, CUPSAT) to identify surface residues predicted to contribute to aggregation-prone patches. A single surface cysteine was engineered at a position that disrupted the predicted aggregation interface while maintaining >20 Å distance from the receptor-binding site. The cysteine-engineered cytokine was expressed in CHO cells and PEGylated with 20 kDa maleimide-PEG under optimized conditions (pH 7.0, 4°C, 2:1 PEG:protein ratio). Mono-PEGylated product was purified by SEC-HPLC.
Outcome:
The site-specifically PEGylated cytokine was soluble at 50 mg/mL with no detectable aggregation by DLS after 6 months at 4°C. Receptor-binding affinity was retained at 92% of the wild-type value. In a mouse inflammation model, the PEGylated cytokine showed 8-fold longer circulating half-life (18 h vs. 2.2 h) and equivalent pharmacodynamic activity at one-quarter the dose frequency. The elimination of aggregation enabled a standard liquid formulation suitable for prefilled syringe delivery, significantly simplifying the manufacturing and distribution logistics.
Case Study 2: PEGylation of an Antisense Oligonucleotide to Improve Delivery and Stability
Background:
An antisense oligonucleotide (ASO) targeting a hepatic disease-related mRNA showed excellent in vitro potency but poor cellular uptake and rapid nuclease degradation in vivo, resulting in undetectable pharmacodynamic activity after systemic administration.
Approach:
Profacgen designed a PEGylation strategy in which a 5 kDa PEG was conjugated to the 3'-terminus of the ASO via a phosphoramidate linkage synthesized during solid-phase oligonucleotide synthesis. The 5 kDa size was selected to balance improved pharmacokinetics with preserved cellular uptake and RNA hybridization kinetics. The PEG-ASO conjugate was purified by RP-HPLC and characterized by ion-exchange chromatography and ESI-MS.
Outcome:
The PEGylated ASO exhibited a 6-fold increase in plasma half-life (4.2 h vs. 0.7 h for unmodified ASO) and a 3-fold improvement in hepatic tissue exposure. Nuclease resistance in 50% human serum increased from 2 hours to over 24 hours. In vivo target mRNA knockdown in mouse liver reached 85% at a dose of 10 mg/kg, compared to 20% for the unmodified ASO at the same dose. The PEG modification also eliminated the dose-limiting renal toxicity observed with the parent ASO, enabling dose escalation to therapeutically effective levels.
Q: What types of molecules can be PEGylated at Profacgen?
A: We provide PEGylation services for a broad range of molecular classes including therapeutic proteins (enzymes, antibodies, cytokines, growth factors, coagulation factors), peptides, antisense oligonucleotides, siRNA, antibody-drug conjugates, and small-molecule drugs. Our capabilities encompass both soluble proteins and membrane-associated targets, as well as complex glycoproteins and multi-subunit assemblies. Please contact us to discuss the feasibility of PEGylating your specific molecule.
Q: How do you determine the optimal PEGylation strategy for my project?
A: Strategy selection involves systematic evaluation of: (1) your protein's amino acid sequence and three-dimensional structure to identify available modification sites and accessibility; (2) location of binding interfaces, active sites, and aggregation-prone regions to guide site selection; (3) desired pharmacokinetic outcomes to guide PEG molecular weight and architecture selection; (4) linker chemistry requirements (stable vs. releasable); (5) downstream purification and analytical needs; and (6) regulatory considerations. We typically perform small-scale screening experiments with multiple PEGylation chemistries and PEG sizes to empirically identify the optimal approach that best balances activity retention with pharmacokinetic improvement.
Q: What PEG molecular weights are available?
A: We offer PEG reagents spanning a wide molecular weight range from 350 Da to 40 kDa, including standard sizes (350 Da, 550 Da, 750 Da, 1 kDa, 2 kDa, 5 kDa, 10 kDa, 20 kDa, 30 kDa, 40 kDa) and custom intermediate sizes. Linear, monodisperse (defined chain length), branched (Y-shaped), and multi-arm (4-arm, 8-arm) architectures are available. Our team can recommend the optimal PEG size and architecture based on your target half-life extension goals, the physicochemical properties of your molecule, and the intended route of administration.
Q: Can you provide GMP-grade PEGylation services?
A: Our research and development-scale PEGylation services support programs through preclinical and early clinical phases (Phase I and II). For Phase III and commercial manufacturing, we have established partnerships with GMP-compliant manufacturing facilities and can facilitate seamless technology transfer of optimized PEGylation processes including standard operating procedures, in-process controls, and release specifications. All development work is conducted with documentation practices (batch records, change control, deviation management) that support future regulatory submissions.
Q: How do you characterize PEGylated products?
A: Our standard analytical package includes: SDS-PAGE and native PAGE for molecular weight and conjugation efficiency assessment; SEC-HPLC for aggregate detection, purity quantification, and molecular weight determination; MALDI-TOF or ESI-MS for exact molecular weight confirmation and stoichiometry verification; RP-HPLC and IEX-HPLC for positional isomer analysis and purity assessment; PEGylation site determination by enzymatic digestion followed by peptide mapping with LC-MS/MS; bioactivity assessment by receptor-binding assays (SPR, ELISA) and relevant cell-based functional assays; and endotoxin, residual PEG reagent, host cell protein, and bioburden testing as required.
References:
Li C, Li T, Tian X, et al. Research progress on the PEGylation of therapeutic proteins and peptides (Tpps). Front Pharmacol. 2024;15:1353626. doi:10.3389/fphar.2024.1353626
Ma M, Di J, Wang C, et al. Site-specific PEGylation of proteins: Insights into structural and functional changes. Acta Pharmaceutica Sinica B. 2025;15(12):6253-6273. doi:10.1016/j.apsb.2025.10.014
Online Inquiry
Fill out this form and one of our experts will respond to you within one business day.
Figure 1. PEGylation of therapeutic proteins and peptides for enhanced pharmacological properties. (Adapted from Li et al., 2024)
Figure 1. Schematic diagram of site-specific PEGylation strategies. (Ma et al., 2025)